Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1832217 | 0.76 | — | — | |
| SCHEMBL23113893 | 0.71 | — | — | |
| SCHEMBL8458175 | 0.71 | — | — | |
| SCHEMBL23266336 | 0.71 | CES1 (0.37) | CES1 | |
| SCHEMBL14152761 | 0.69 | CES1 (0.36) | CES1 | |
| SCHEMBL9987095 | 0.69 | P2RX7 (0.43) | CES1SMN1; SMN2RAB9AALDH1A1HPGD | |
| SCHEMBL1110118 | 0.67 | CYP1A2 (0.42) | CES1ALDH1A1KMT2A | |
| SCHEMBL14338424 | 0.66 | ALDH1A1 (0.36) | SMN1; SMN2RAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL12714300 | 0.65 | KDM4E (0.45) | SMN1; SMN2RAB9AALDH1A1HPGD | |
| SCHEMBL15780518 | 0.65 | APLNR (0.41) | SMN1; SMN2RAB9AALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677667-A | Bifunctional chimera heterocyclic compound and application thereof as androgen receptor degrading agent | 海创药业股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-9353102-B2 | Non-annulated thiophenylamides | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150183778-A1 | New non-annulated thiophenylamides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183778-A1 | New non-annulated thiophenylamides | NAT1, NCL, NTSR1 | CES1 2173/4885SMN1; SMN2 3864/4885RAB9A 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.